Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
相关临床试验
19
6 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
2017
进行中（未招募）
6
31.6%
Available
2
10.5%
已完成
6
31.6%
招募中
4
21.1%
终止
1
5.3%
- Merck KGaA announced a definitive agreement to acquire U.S. biotech firm Bio-Techne for $11.3 billion, representing a 24% premium at $73 per share. - The deal is Merck's largest acquisition since the $17 billion Sigma-Aldrich purchase in 2014 and the first major move under new CEO Kai Beckmann. - Bio-Techne brings a portfolio of 6,000 proteins, 425,000 antibodies, reagents, analytical instruments, and services that strengthen Merck's cell and gene therapy capabilities. - The transaction is expected to close by late 2026 or early 2027, with approximately €140 million in cost savings anticipated by the third year post-closing.
- Beeline Medicines launched from stealth with a $300 million Series A funding round from Bain Capital to develop precision therapies for immune diseases. - The company's lead asset afimetoran, licensed from Bristol Myers Squibb, is an oral treatment for systemic lupus erythematosus currently in Phase 2 trials expected to complete in the second half of this year. - Beeline's pipeline includes five experimental medicines from Bristol Myers targeting various immune conditions including atopic dermatitis, plaque psoriasis, and rare immunological diseases. - The company is led by Saqib Islam, former CEO of SpringWorks Therapeutics, which was acquired by Merck KGaA for nearly $4 billion last year.
- Gintemetostat (KTX-1001), a first-in-class oral MMSET/NSD2 inhibitor, demonstrated encouraging antitumor activity and manageable safety in 40 heavily pretreated patients with relapsed/refractory multiple myeloma. - Among treated patients, 1 achieved very good partial response, 1 had partial response, 2 had minimal response, and 12 had stable disease, with particularly promising results in t(4;14)-positive patients. - The therapy showed a favorable safety profile with 75% experiencing treatment-related adverse events, while 12 patients remained on treatment at data cutoff. - K36 Therapeutics plans to advance into dose-expansion phase evaluating combinations with proteasome inhibitors, IMiDs, and next-generation CELMoDs like mezigdomide.
- Extended treatment with mirdametinib led to improved confirmed overall response rates in both adult (47%) and pediatric (55%) patients with NF1-associated symptomatic plexiform neurofibromas. - Deep responses, defined as greater than 50% tumor volume reduction, increased significantly with longer treatment duration, reaching 67% of adult responders and 61% of pediatric responders. - The MEK1/2 inhibitor demonstrated durable responses with 85% of adult patients and 84% of pediatric patients maintaining responses for at least 12 months. - No new safety signals emerged during long-term follow-up, with mirdametinib maintaining a manageable safety profile consistent with previous data.
- Merck has opened a €150 million, 3,000-square-meter cleanroom facility in Blarney, Cork, to manufacture advanced filtration products for vaccines, monoclonal antibodies, and cell and gene therapies. - The facility is part of Merck's largest Life Science investment in Ireland totaling €440 million across Cork operations, expected to create over 200 new jobs by 2028. - Production is scheduled to begin in Q4 2025, focusing on filtration devices for aseptic processing, tangential-flow filtration, and virus filtration technologies. - The investment represents part of Merck's €2 billion global Life Science expansion program launched in 2020 to meet growing demand for life-saving therapies.
- The European Commission has granted conditional approval for Ezmekly (mirdametinib), the first therapy approved for both adults and children with neurofibromatosis type 1-associated plexiform neurofibromas. - The approval is based on the ReNeu Phase 2b trial results showing objective response rates of 41% in adults and 52% in children, with median tumor volume reductions of approximately 40% in both populations. - Ezmekly is a selective MEK 1/2 inhibitor that blocks the RAF-MEK-ERK pathway, addressing a significant unmet need for patients with symptomatic, inoperable plexiform neurofibromas aged 2 years and above. - The drug demonstrated a manageable safety profile with the most common adverse reactions including dermatitis acneiform, diarrhea, and elevated blood creatine phosphokinase levels.
- Pharmaceutical M&A activity is experiencing a significant rebound with major deals including Novartis's $1.7 billion acquisition of Regulus Therapeutics and Merck KGaA's $3.9 billion purchase of SpringWorks Therapeutics. - Small-cap biotechs are becoming prime acquisition targets as 22% of the sector now trades below cash value, the highest level in nine years, creating opportunities for pharma companies with strong balance sheets. - Major pharmaceutical companies including Pfizer, Bristol Myers Squibb, and Sanofi have signaled business development as a top priority, with Pfizer specifically targeting $10-15 billion acquisitions to rebuild its pipeline. - Deal momentum in biotech and pharma sectors rose 63% in Q1 2025 after falling 26% over the previous 12 months, indicating a market recovery despite ongoing tariff concerns.
- CG Oncology's cretostimogene grenadenorepvec demonstrated a 75.5% complete response rate in high-risk BCG-unresponsive non-muscle invasive bladder cancer patients, with 34% maintaining complete response at 24 months. - The FDA has granted Fast Track and Breakthrough Therapy designations to cretostimogene, potentially expediting its regulatory pathway for a disease with limited treatment options. - The drug's 27.9-month median duration of response may provide a competitive edge over Johnson & Johnson's TAR-200, positioning CG Oncology as a significant player in the bladder cancer treatment landscape.
- German pharmaceutical giant Merck KGaA has agreed to acquire Connecticut-based SpringWorks Therapeutics for $3.9 billion, paying $47 per share in cash, representing a 26% premium over SpringWorks' unaffected 20-day average price. - The acquisition gives Merck KGaA immediate access to SpringWorks' two FDA-approved rare disease treatments: Ogsiveo for desmoid tumors and Gomekli for neurofibromatosis type 1-related tumors. - The transaction, expected to close in the second half of 2025 pending regulatory approvals, aligns with Merck KGaA's strategic expansion in the U.S. market and is projected to contribute to earnings by 2027.
- SpringWorks Therapeutics expects the European Medicines Agency's CHMP to issue an opinion on nirogacestat for adult desmoid tumors in Q2 2025, potentially expanding access beyond its current FDA approval. - Nirogacestat, marketed as OGSIVEO in the US, is an oral gamma secretase inhibitor and the first FDA-approved therapy specifically for adults with desmoid tumors, addressing a significant unmet need. - SpringWorks continues to build its rare disease portfolio, which includes GOMEKLI (mirdametinib) for neurofibromatosis type 1, while advancing additional targeted therapies for solid tumors and hematological cancers.
